Advertisement
Singapore markets closed

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,010.74
    -60.89 (-1.20%)
     

  • Dow

    37,863.85
    -597.07 (-1.55%)
     

  • Nasdaq

    15,455.09
    -257.66 (-1.64%)
     

  • Bitcoin USD

    63,861.48
    -987.76 (-1.52%)
     

  • CMC Crypto 200

    1,374.81
    -7.76 (-0.56%)
     

  • FTSE 100

    8,078.06
    +37.68 (+0.47%)
     

  • Gold

    2,345.20
    +6.80 (+0.29%)
     

  • Crude Oil

    82.27
    -0.54 (-0.65%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Accenture's (ACN) INTIENT to Aid Bayer in Drug Development

Zacks Equity Research

Accenture plc ACN yesterday announced that it collaborated with Bayer to implement its INTIENT Clinical platform in Bayer’s drug development processes.

The platform, which was built in collaboration with Oracle ORCL, captures, imports, stores and standardizes complex clinal data. It helps in fast running of clinical trials, with high transparency and easy access to trial information. It can quickly combine new technology, advanced analytics and applied intelligence to support betterment of patient outcomes.

Mike Stapleton, a managing director in Accenture’s Life Sciences practice, said, “We are excited to work with Bayer to provide new insights on their clinical trials, so they can bring the important treatments they develop to patients faster and with the highest quality.”

The collaboration will benefit Accenture’s Life Sciences industry group. It is part of the company’s Products segment and serves pharmaceutical, medical technology and biotechnology companies.

ADVERTISEMENT

Products’ revenues increased 4% year over year on a reported basis and 8% in local currency in the last reported quarter. Notably, growth in Life Sciences across all geographic regions significantly contributed to the segment’s performance.

We observe that shares of Accenture have gained 38.8% year to date, outperforming the 32% growth of the industry it belongs to and 27.3% rally of the Zacks S&P 500 composite.

 

 

Zacks Rank and Stocks to Consider

Accenture currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader Zacks Business Services sector are Huron Consulting HURN and Charles River Associates CRAI, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Long-term expected earnings (three to five years) growth rates for Huron and Charles River are 13.5% and 13%, respectively.

5 Stocks Set to Double

Zacks experts released their picks to gain +100% or more in 2020. One is a famous cutting-edge food company that is “hiding in plain sight.” Swamped with competitors and ignored by Wall Street, its stock price floundered. Now, suddenly, it acquired a company that gives it an advantage none of its peers have.

Today, see all 5 stocks with extreme growth potential >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Oracle Corporation (ORCL) : Free Stock Analysis Report
 
Charles River Associates (CRAI) : Free Stock Analysis Report
 
Accenture PLC (ACN) : Free Stock Analysis Report
 
Huron Consulting Group Inc. (HURN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research